WO2022139487A1 - 신규한 펩타이드 및 이의 용도 - Google Patents
신규한 펩타이드 및 이의 용도 Download PDFInfo
- Publication number
- WO2022139487A1 WO2022139487A1 PCT/KR2021/019658 KR2021019658W WO2022139487A1 WO 2022139487 A1 WO2022139487 A1 WO 2022139487A1 KR 2021019658 W KR2021019658 W KR 2021019658W WO 2022139487 A1 WO2022139487 A1 WO 2022139487A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- pharmaceutical composition
- preventing
- composition
- obesity
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 90
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 28
- 239000008103 glucose Substances 0.000 claims abstract description 25
- 230000004069 differentiation Effects 0.000 claims abstract description 12
- 210000001789 adipocyte Anatomy 0.000 claims abstract description 10
- 235000019789 appetite Nutrition 0.000 claims abstract description 8
- 230000036528 appetite Effects 0.000 claims abstract description 8
- 230000006372 lipid accumulation Effects 0.000 claims abstract description 6
- 230000003914 insulin secretion Effects 0.000 claims abstract description 5
- 208000008589 Obesity Diseases 0.000 claims description 35
- 235000020824 obesity Nutrition 0.000 claims description 35
- 239000008194 pharmaceutical composition Substances 0.000 claims description 24
- 208000002249 Diabetes Complications Diseases 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 206010012655 Diabetic complications Diseases 0.000 claims description 10
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 claims description 7
- 210000000577 adipose tissue Anatomy 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 101710151321 Melanostatin Proteins 0.000 claims description 6
- 102400000064 Neuropeptide Y Human genes 0.000 claims description 6
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 102000054930 Agouti-Related Human genes 0.000 claims description 4
- 101710127426 Agouti-related protein Proteins 0.000 claims description 4
- 150000001413 amino acids Chemical group 0.000 claims description 2
- 230000019439 energy homeostasis Effects 0.000 claims description 2
- 230000035924 thermogenesis Effects 0.000 claims description 2
- 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 claims 2
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000003880 negative regulation of appetite Effects 0.000 claims 1
- 102100022936 ATPase inhibitor, mitochondrial Human genes 0.000 abstract description 18
- 101710085568 ATPase inhibitor, mitochondrial Proteins 0.000 abstract description 18
- 230000003579 anti-obesity Effects 0.000 abstract description 12
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 9
- 238000010171 animal model Methods 0.000 abstract description 5
- 230000003178 anti-diabetic effect Effects 0.000 abstract description 5
- 239000003472 antidiabetic agent Substances 0.000 abstract description 3
- 235000009200 high fat diet Nutrition 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 20
- 230000000694 effects Effects 0.000 description 17
- 102000004196 processed proteins & peptides Human genes 0.000 description 16
- 235000021590 normal diet Nutrition 0.000 description 15
- 230000008859 change Effects 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 11
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 230000002265 prevention Effects 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- -1 for example Substances 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 230000004584 weight gain Effects 0.000 description 6
- 235000019786 weight gain Nutrition 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 102100029820 Mitochondrial brown fat uncoupling protein 1 Human genes 0.000 description 5
- 230000006978 adaptation Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 238000009395 breeding Methods 0.000 description 5
- 230000001488 breeding effect Effects 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000002267 hypothalamic effect Effects 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 4
- 101710168309 CCAAT/enhancer-binding protein alpha Proteins 0.000 description 4
- 102100034808 CCAAT/enhancer-binding protein alpha Human genes 0.000 description 4
- 102000013948 Fatty acid-binding protein 4 Human genes 0.000 description 4
- 108050003772 Fatty acid-binding protein 4 Proteins 0.000 description 4
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 4
- 102000043296 Lipoprotein lipases Human genes 0.000 description 4
- 108010016731 PPAR gamma Proteins 0.000 description 4
- 102000012132 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 235000018823 dietary intake Nutrition 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000004153 glucose metabolism Effects 0.000 description 4
- 239000007928 intraperitoneal injection Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 229960000074 biopharmaceutical Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 229940090044 injection Drugs 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 102000011690 Adiponectin Human genes 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000011759 adipose tissue development Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000002830 appetite depressant Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000013118 diabetic mouse model Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229940093181 glucose injection Drugs 0.000 description 2
- 238000007446 glucose tolerance test Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 108700021677 Agouti-Related Proteins 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004470 DL Methionine Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 108091016218 adiponectin binding proteins Proteins 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000021407 appetite control Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 description 1
- 229960004874 choline bitartrate Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000004155 insulin signaling pathway Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 102000005861 leptin receptors Human genes 0.000 description 1
- 108010019813 leptin receptors Proteins 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 238000013116 obese mouse model Methods 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Definitions
- the present invention relates to novel peptides derived from biological proteins and their anti-obesity and anti-diabetic uses.
- Biopharmaceuticals are mainly protein drugs composed of hormones and antibodies, and additionally composed of genomes. Unlike pharmaceuticals centered on chemicals made of low-molecular substances, biopharmaceuticals are mostly made of high-molecular substances, so various problems arise from their size. Representatively, there are problems in the active aspect such as decreased accessibility to target substances and autoimmune reactions due to large size, and industrial problems such as increase in cost and time required due to increased complexity in production as the size increases. This is a phenomenon that occurs because ancillary structures exist as components in addition to the active site that has a major influence on the function of the protein. Significant improvements can be made in terms of several side effects and costs of pharmaceuticals.
- the present inventors focused on the invention of a peptide derived from IF1 protein to improve the function of IF1 (ATPase inhibitory factor 1) protein expressed in vivo.
- IF1 ATPase inhibitory factor 1
- one aspect of the present invention provides a peptide comprising the amino acid sequence represented by SEQ ID NO: 1 or 2 derived from a biological protein.
- IF1 ATPase inhibitory factor 1
- IF1 ATPase inhibitory factor 1
- the present inventors researched to find peptides having novel functionality in the IF1 protein (SEQ ID NOs: 3 and 4), and discovered the peptides of SEQ ID NOs: 1 and 2 having anti-obesity and anti-diabetic activity.
- Another aspect of the present invention provides a pharmaceutical composition for preventing or treating obesity comprising the peptide as an active ingredient.
- prevention refers to any action of inhibiting the progression of a disease or delaying the onset of a disease by administration of the pharmaceutical composition according to the present invention.
- treatment refers to any action in which symptoms of a disease are improved or beneficially changed by administration of the pharmaceutical composition according to the present invention.
- the present inventors administered a high-fat diet and a functional peptide to mice together to confirm the physiological activity of a peptide derived from IF1 protein (hereinafter referred to as a functional peptide) (obesity prevention experiment), or a high-fat diet to a mouse inducing obesity and functional peptide were administered together (obesity treatment experiment).
- a functional peptide a peptide derived from IF1 protein
- composition can be usefully used for both prevention and treatment of obesity.
- the functional peptide inhibits lipid accumulation and differentiation of adipocytes, which are indicators of adipogenesis in adipocytes: peroxisome proliferator-activated receptor gamma (PPAR ⁇ ), adiponectin, and fatty acid-binding protein 4 (FABP4). , by suppressing the expression of C/EBPa (CCAAT/enhancer-binding protein alpha) and LPL (lipoprotein lipase) genes.
- PPAR ⁇ peroxisome proliferator-activated receptor gamma
- FABP4 fatty acid-binding protein 4
- the functional peptide suppresses appetite, which can be achieved by suppressing the expression of AgRP (agouti-related protein) and NPY (neuropeptide Y), which are peptides that promote appetite in hypothalamic cells.
- the composition for preventing or treating obesity may exhibit an anti-obesity effect by suppressing the differentiation of adipocytes and suppressing appetite.
- Another aspect of the present invention provides a pharmaceutical composition for preventing or treating diabetes or diabetic complications comprising the functional peptide as an active ingredient.
- the present inventors performed a glucose tolerance test by injecting a glucose solution after fasting an obesity-induced mouse and a type 2 diabetic mouse. As a result, it was confirmed that the blood glucose level was decreased by administration of the functional peptide ( FIGS. 4 and 5A, 5B ), and insulin secretion increased ( FIG. 5E ).
- the composition for preventing or treating diabetes may exhibit an antidiabetic effect by improving glucose tolerance and promoting insulin secretion.
- Diabetic complications refer to complications such as myocardial infarction, stroke, retinopathy, and renal failure caused by damage to the blood vessel wall due to prolonged hyperglycemia. If the hyperglycemic state is improved, diabetic complications can also be improved, so the functional peptide of the present invention can also be used for preventing or treating diabetic complications.
- the pharmaceutical composition of the present invention may be prepared in a form further comprising an appropriate carrier, excipient or diluent commonly used in the preparation of the pharmaceutical composition, wherein the carrier includes a non-naturally occurring carrier. can do.
- the pharmaceutical composition is each formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc., external preparations, suppositories and sterile injection solutions according to conventional methods to be used.
- powders granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc.
- external preparations suppositories and sterile injection solutions according to conventional methods to be used.
- carriers, excipients and diluents that may be included in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
- it is prepared using commonly used diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants.
- Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations include at least one excipient, for example, starch, calcium carbonate, sucrose or lactose. It is prepared by mixing (lactose), gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used.
- excipient for example, starch, calcium carbonate, sucrose or lactose. It is prepared by mixing (lactose), gelatin, etc.
- lubricants such as magnesium stearate and talc are also used.
- Liquid preparations for oral use include suspensions, solutions, emulsions, syrups, etc., and various excipients such as wetting agents, sweeteners, fragrances, and preservatives, in addition to simple diluents such as water and liquid paraffin, which are commonly used. have.
- Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories.
- Non-aqueous solvents and suspending agents include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate.
- the pharmaceutical composition may be in the form of a sterile injectable preparation as a sterile injectable aqueous or oleaginous suspension.
- suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents (eg, Tween 80) and suspending agents.
- the sterile injectable preparation may also be a sterile injectable solution or suspension (eg, a solution in 1,3-butanediol) in a non-toxic parenterally acceptable diluent or solvent.
- Vehicles and solvents that can be used permissibly include mannitol, water, Ringel's solution and isotonic sodium chloride solution.
- sterile, non-volatile oils are conventionally employed as the solvent or suspending medium.
- any non-volatile, less irritating oil may be used, including synthetic mono or diglycerides.
- Fatty acids such as oleic acid and its glyceride derivatives are useful in injectable formulations as are pharmaceutically acceptable natural oils (eg olive oil or castor oil), especially their polyoxyethylated ones.
- Parenteral administration of a pharmaceutical composition according to the present invention is particularly useful when the desired treatment involves a site or organ easily accessible by topical application.
- Carriers for topical administration of the compounds of the present invention include, but are not limited to, mineral oil, liquid paraffin, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compounds, emulsifying waxes and water.
- the content of the active ingredient included in the pharmaceutical composition of the present invention is not particularly limited thereto, but may be included in an amount of 0.0001 to 50% by weight, more preferably 0.01 to 10% by weight, based on the total weight of the final composition. .
- Another aspect of the present invention is a method for treating obesity comprising administering the pharmaceutical composition for preventing or treating obesity to an individual in need of treatment, and administering the pharmaceutical composition for preventing or treating diabetes or diabetic complications to an individual in need of treatment It provides a method of treating diabetes or diabetic complications, comprising the step of administering.
- the method of administering the pharmaceutical composition may be administered orally or parenterally as described above, and the dosage of the pharmaceutical composition may be determined by a treating expert.
- the present invention relates to a biological protein-derived peptide and its pharmaceutical use, wherein the peptide suppresses appetite in an obese animal model, inhibits the lipid accumulation and differentiation of adipocytes, and promotes insulin secretion and improves glucose tolerance in a diabetic animal model Therefore, it can be usefully used for anti-obesity and anti-diabetic purposes.
- A is the result of confirming the change in body weight while administering the IF1-derived peptide (hereinafter referred to as a functional peptide) to a mouse model induced by obesity with a high-fat diet for 6 weeks
- B is the final result after administration for 6 weeks
- C to E are the ratio of total body weight change during the administration period (C), the dietary intake efficiency during the administration period (D) and daily during the administration period after administration of the high-fat diet and the functional peptide to the mouse.
- E results of checking the dietary intake
- control control group
- peptide functional peptide administration group (same in the drawings below).
- Figure 2 shows the serum triglyceride level (A), serum free fatty acid level (B), area occupied by fat spheres in adipose tissue (C) and adipose tissue after administration of a high-fat diet and functional peptide to mice together for 30 days
- the result of confirming the change in UCP-1 expression (D), and E is the result of confirming the change in UCP-1 expression in adipose tissue after administration of a high-fat diet and a functional peptide together for 6 weeks to an obesity-induced mouse.
- A is the result of confirming the expression changes of genes related to adipocyte differentiation and growth after treatment with functional peptides in the differentiation process of adipocytes
- B and C are hypothalamic cells with mouse-derived and human-derived functional peptides, respectively. It is the result of confirming the expression change of appetite-promoting genes after treatment.
- A is the result of checking the blood glucose level by injecting a glucose solution after fasting the type 2 diabetes mouse model
- B is the result of quantifying the total blood glucose change
- C is the weight of the pancreas isolated from the mouse.
- D is the result of comparing the result of adjusting the pancreatic weight to the mouse weight
- E is the result of confirming the blood insulin concentration.
- IF1 protein and IF1-derived peptide (hereinafter, referred to as a functional peptide; SEQ ID NO: 1 or 2) coding sequences were inserted into pGEX-4T-1 and pet28a vectors, respectively.
- the vector was transformed into BL21 (DE3), an E. coli strain for expression, to establish a cell model stably expressing IF1 and functional peptides. After culturing the corresponding E. coli cells, protein expression was induced by treatment with 1 mM IPTG (Isopropyl ⁇ -D-1-thiogalactopyranoside).
- Orient Bio received a 4-week-old C57BL/6J male and gave him a normal diet (Normal diet chow; ND) for 1 week, and it took time to adapt. At this time, the temperature of the breeding space was maintained at 18 ⁇ 24°C and the humidity at 50 ⁇ 60% as the entire breeding environment during the experiment period, and free feeding was implemented during both the adaptation period and the experiment period.
- the mice that passed the adaptation period were divided into an obesity prevention experimental group and an obesity treatment experimental group, and were bred for each purpose.
- a normal diet and a high-fat diet were prepared and provided as shown in Table 2 below.
- Obesity was induced by providing a high-fat diet (see Table 1) for 8 weeks after an adaptation period of 1 week.
- Example 2-1 PBS and peptide were administered through intraperitoneal injection once daily during the experimental period.
- the corresponding conditions are as follows.
- mice in the obesity prevention and obesity treatment groups were fasted for 12 hours, the tissues were separated and stored, and the serum was separated.
- the reduction of free fatty acids (FIG. 2A) and triglycerides (FIG. 2B) in the functional peptide administration group compared to the control group.
- DMEM Primary differentiation medium
- FBS Fetal Bovine Serum
- Antibiotics 0.5 mM 3-isobutyl-1-methylxanthine, 1 uM dexametahasone, 10 ⁇ g/ml Insulin to differentiate 3T3-L1 adipocytes into adipocytes
- secondary differentiation medium DMEM, 10% FBS, 1% Antibiotics, 10 ⁇ g/ml Insulin
- each substance control group: PBS, experimental group: functional peptide 100 nM was added to the medium during the differentiation period and used.
- PPAR ⁇ peroxisome proliferator-activated receptor gamma
- adiponectin adiponectin
- FABP4 fatty acid-binding protein 4
- C/EBPa C/EBPa
- LPL lipoprotein lipase
- the hypothalamic cells were treated with PBS (control group) and 100 nM mouse-derived functional peptide (experimental group) for 24 hours. After the end of the experiment, cells were recovered and the levels of Agrp (agouti-related peptide) and NPY (neuropeptide Y) genes, which are known to promote appetite, were observed. It was confirmed that the functional peptide also had an appetite suppressant action (FIG. 3B).
- Type 2 diabetic mice (db/db) were used to confirm the effect of the functional peptide on glucose metabolism.
- the db/db model corresponding to type 2 diabetic mice is an animal model in which genetic mutations are induced in the leptin receptor responsible for dietary control, and is a representative model of diabetes in which obesity is induced due to inability to regulate the insulin signaling pathway and satiety.
- mice 8-week-old male C57BLKS/6J-db/m+ (Hetero mutant) and C57BLKS/6J-db/db (Homo mutant) mice were distributed from the Central Lab and fed a normal diet (Normal diet chow; ND) for 1 week. provided and took time to adapt. At this time, the temperature of the breeding space was maintained at 18 ⁇ 24°C and the humidity at 50 ⁇ 60% as the entire breeding environment during the experiment period, and free feeding was implemented during both the adaptation period and the experiment period.
- Normal diet chow Normal diet chow
- mice were divided into a control group and an experimental group, and each was bred for 44 days under the following conditions.
- the normal diet was prepared and provided as shown in Table 1 above.
- mice were fasted for 14 hours and then euthanized, and then dissected and tissues were collected for further analysis. In addition, blood was collected, and serum was separated and analyzed by centrifugation.
- glucose tolerance improvement effect due to obesity and impaired glucose tolerance due to genetic mutations was confirmed through glucose tolerance tests.
- Example 2-1 the obesity prevention mouse model of Example 2-1 was fasted for 12 hours, and a 20% glucose solution was injected intraperitoneally to observe the change in blood glucose level.
- substances corresponding to each group were injected as in Example 3-1 30 minutes before the injection of the glucose solution.
- the blood sugar level decreased in the functional peptide administration group from 30 minutes after the glucose injection.
- FIG. 4 a decrease in blood glucose level by the functional peptide was confirmed (FIG. 4), confirming that the functional peptide has an effect of improving glucose metabolism.
- Example 3-1 The diabetic mouse model of Example 3-1 was fasted for 12 hours, and a 20% glucose solution was injected by intraperitoneal injection to observe the change in blood glucose level. At this time, substances corresponding to each group were injected as in Example 3-1 30 minutes before the injection of the glucose solution. As a result of checking the change in blood sugar level, it was found that the blood sugar level significantly decreased in the functional peptide group compared to the db/db control group after 60, 90, and 12 minutes of glucose injection. In addition, as a result of quantifying the total blood glucose change (blood glucose level x time; GLUAUC), a decrease in blood glucose level by the functional peptide was confirmed (FIG. 5B), confirming that the functional peptide has an effect of improving glucose metabolism.
- blood glucose level x time blood glucose level x time; GLUAUC
- Example 3-1 To observe changes and disorders in hormone secretion resulting from diabetes, the tissue isolated from the diabetic mouse model of Example 3-1 was analyzed, and the weight of the pancreas, which plays a major role in hormone secretion, and blood of insulin hormone inducing glucose absorption My concentration was specifically tested.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
서열번호 | 서열명칭 | 서열 (Sequence) |
1 | 기능성 펩타이드 (마우스) |
VSDSSDSMDTGAGSIREAGGAFGKREKAEEDRYFREKTKEQLAALRK |
2 | 기능성 펩타이드 (인간) |
GSDQSENVDRGAGSIREAGGAFGKREQAEEERYFRAQSREQLAALKK |
3 | IF1 (마우스) |
VSDSSDSMDTGAGSIREAGGAFGKREKAEEDRYFREKTKEQLAALRKHHEDEIDHHSKEIERLQKQIERHKKKIQQLKNNH |
4 | IF1 (인간) |
GSDQSENVDRGAGSIREAGGAFGKREQAEEERYFRAQSREQLAALKKHHEEEIVHHKKEIERLQKEIERHKQKIKMLKHDD |
성분 | 정상 식이 (g) | 고지방 식이 (g) |
corn starch | 15 | 15 |
Casein | 20 | 20 |
Sucrose | 50 | 34 |
corn oil | 5 | 3 |
Mineral mix | 3.5 | 3.5 |
Vitamin mix | 1 | 1 |
Cellulose | 5 | 5 |
DL-methionine | 0.3 | 0.3 |
choline bitartrate | 0.2 | 0.2 |
Lard | 17 | |
Cholesterol | 1 | |
BHT | 0.001 | 0.001 |
Total | 100 (g) | 100 (g) |
Claims (11)
- 서열번호 1 또는 2로 표시되는 아미노산 서열을 포함하는 펩타이드.
- 제1항의 펩타이드를 유효성분으로 포함하는 비만의 예방 또는 치료용 약학 조성물.
- 제2항에 있어서, 상기 조성물은 식욕을 억제하는, 비만의 예방 또는 치료용 약학 조성물.
- 제3항에 있어서, 상기 식욕 억제는 AgRP (agouti-related protein) 또는 NPY (neuropeptide Y) 펩타이드 억제에 의한 것인, 비만의 예방 또는 치료용 약학 조성물.
- 제2항에 있어서, 상기 조성물은 지방세포의 지질 축적 및 분화를 억제하는, 비만의 예방 또는 치료용 약학 조성물.
- 제2항에 있어서, 상기 조성물은 지방조직 내 열 발생과 에너지 항상성을 활성화시키는 UCP-1(uncoupling protein-1) 유전자의 발현을 증가시키는, 비만의 예방 또는 치료용 약학 조성물.
- 제1항의 펩타이드를 유효성분으로 포함하는 당뇨병 또는 당뇨합병증의 예방 또는 치료용 약학 조성물.
- 제7항에 있어서, 상기 조성물은 인슐린 분비를 촉진하는, 당뇨병 또는 당뇨합병증의 예방 또는 치료용 약학 조성물.
- 제7항에 있어서, 상기 조성물은 내당능을 개선하는, 당뇨병 또는 당뇨합병증의 예방 또는 치료용 약학 조성물.
- 제1항의 조성물을 치료가 필요한 개체에 투여하는 단계를 포함하는 비만 치료 방법.
- 제7항의 조성물을 치료가 필요한 개체에 투여하는 단계를 포함하는 당뇨병 또는 당뇨합병증 치료 방법.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/258,578 US20240034758A1 (en) | 2020-12-22 | 2021-12-22 | Novel peptide and use thereof |
EP21911553.2A EP4269428A1 (en) | 2020-12-22 | 2021-12-22 | Novel peptide and use thereof |
JP2023562446A JP2024503540A (ja) | 2020-12-22 | 2021-12-22 | 新規ペプチドおよびその用途 |
CN202180087261.XA CN116888145A (zh) | 2020-12-22 | 2021-12-22 | 新型肽及其用途 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20200180639 | 2020-12-22 | ||
KR10-2020-0180639 | 2020-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022139487A1 true WO2022139487A1 (ko) | 2022-06-30 |
Family
ID=82158525
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/019658 WO2022139487A1 (ko) | 2020-12-22 | 2021-12-22 | 신규한 펩타이드 및 이의 용도 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20240034758A1 (ko) |
EP (1) | EP4269428A1 (ko) |
JP (1) | JP2024503540A (ko) |
KR (1) | KR20220090473A (ko) |
CN (1) | CN116888145A (ko) |
WO (1) | WO2022139487A1 (ko) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5906923A (en) * | 1996-10-02 | 1999-05-25 | Incyte Pharmaceuticals, Inc. | ATPase inhibitor |
US20040072739A1 (en) * | 1999-11-10 | 2004-04-15 | Anderson Christen M. | Compositions and methods for regulating endogenous inhibitor of ATP synthase, including treatment for diabetes |
KR20180107368A (ko) * | 2017-03-17 | 2018-10-02 | 고려대학교 산학협력단 | Atpif1을 함유하는 당뇨 치료용 약학조성물 |
WO2020055186A1 (ko) * | 2018-09-14 | 2020-03-19 | 고려대학교 산학협력단 | If1 을 유효성분으로 함유하는 비만 또는 근감소증의 예방 또는 치료용 약학 조성물 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3045599A1 (en) | 2016-12-16 | 2018-06-21 | Avixgen Inc | Cytoplasmic transduction peptide and intracellular messenger comprising same |
-
2021
- 2021-12-22 WO PCT/KR2021/019658 patent/WO2022139487A1/ko active Application Filing
- 2021-12-22 EP EP21911553.2A patent/EP4269428A1/en active Pending
- 2021-12-22 JP JP2023562446A patent/JP2024503540A/ja active Pending
- 2021-12-22 US US18/258,578 patent/US20240034758A1/en active Pending
- 2021-12-22 KR KR1020210185303A patent/KR20220090473A/ko not_active Application Discontinuation
- 2021-12-22 CN CN202180087261.XA patent/CN116888145A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5906923A (en) * | 1996-10-02 | 1999-05-25 | Incyte Pharmaceuticals, Inc. | ATPase inhibitor |
US20040072739A1 (en) * | 1999-11-10 | 2004-04-15 | Anderson Christen M. | Compositions and methods for regulating endogenous inhibitor of ATP synthase, including treatment for diabetes |
KR20180107368A (ko) * | 2017-03-17 | 2018-10-02 | 고려대학교 산학협력단 | Atpif1을 함유하는 당뇨 치료용 약학조성물 |
WO2020055186A1 (ko) * | 2018-09-14 | 2020-03-19 | 고려대학교 산학협력단 | If1 을 유효성분으로 함유하는 비만 또는 근감소증의 예방 또는 치료용 약학 조성물 |
Non-Patent Citations (1)
Title |
---|
ANNELISE GENOUX, PONS VéRONIQUE, RADOJKOVIC CLAUDIA, ROUX-DALVAI FLORENCE, COMBES GUILLAUME, ROLLAND CORINNE, MALET NICOLE, M: "Mitochondrial Inhibitory Factor 1 (IF1) Is Present in Human Serum and Is Positively Correlated with HDL-Cholesterol", PLOS ONE, vol. 6, no. 9, 14 September 2011 (2011-09-14), pages 1 - 8, XP055561582, DOI: 10.1371/journal.pone.0023949 * |
Also Published As
Publication number | Publication date |
---|---|
JP2024503540A (ja) | 2024-01-25 |
US20240034758A1 (en) | 2024-02-01 |
CN116888145A (zh) | 2023-10-13 |
EP4269428A1 (en) | 2023-11-01 |
KR20220090473A (ko) | 2022-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018128515A1 (ko) | 니클로사이드를 함유하는 Axin-GSK3 단백질 결합 관련 질환 치료용 약학조성물 | |
WO2018194309A1 (ko) | 인디루빈 유도체를 유효성분으로 포함하는 약학 조성물 | |
CA2152420A1 (en) | Therapeutic agent for the treatment of xerostomia | |
WO2022131428A1 (ko) | 오를리스타트 및 아커만시아 뮤시니필라 eb-amdk19 균주를 포함하는 조성물 | |
WO2022139487A1 (ko) | 신규한 펩타이드 및 이의 용도 | |
WO2015178653A1 (ko) | Akkermansia muciniphila 균에서 유래하는 세포밖 소포를 유효성분으로 함유하는 대사질환의 치료 또는 예방용 조성물 | |
WO2020262838A1 (ko) | 천연물 추출물을 포함하는 안정성이 개선된 약제학적 조성물 | |
WO2022139489A1 (ko) | 알코올성 및 비알코올성 지방간의 예방 또는 치료용 약학 조성물 | |
WO2023042959A1 (ko) | 복합 진세노사이드 조성물을 포함하는 항염증 조성물 | |
WO2021182913A1 (ko) | 태반 추출물을 포함하는 간 질환 예방 또는 치료용 및 간 기능 개선용 조성물 | |
WO2021033995A1 (ko) | 초과 추출물을 함유하는 근육 감소 관련 질병의 예방, 개선, 또는 치료용 조성물 | |
WO2014185607A1 (ko) | 폐섬유화증 예방 또는 치료용 약학 조성물 | |
JP7023518B2 (ja) | 分泌障害の処置のための方法および組成物 | |
WO2023153533A1 (ko) | 후박 추출물을 유효성분으로 함유하는 근육 질환 예방 및 치료용 조성물 | |
WO2021006607A1 (ko) | Lgi3 유래 펩타이드를 유효성분으로 포함하는 당뇨병의 예방, 치료, 또는 개선용 조성물 | |
WO2021002645A1 (ko) | 하이드로겔 및 egfr 리간드를 유효성분으로 포함하는 당 배출용 조성물 | |
WO2023058996A1 (ko) | 항염증 활성을 갖는 펩타이드와 이의 용도 | |
WO2022211303A1 (ko) | 3-(4-(벤질옥시)페닐)헥스-4-이노익산 유도체의 신규 용도 | |
WO2022114459A1 (ko) | 모노메틸푸마레이트를 유효성분으로 포함하는 장기 섬유증의 예방 또는 치료용 약학적 조성물 | |
WO2022173273A1 (ko) | 아로니아 추출물을 포함하는 근육 질환의 예방 또는 치료용 조성물 | |
WO2023022522A1 (ko) | 지방간염, 지방증 또는 섬유증의 예방 또는 치료용 복합 제제 | |
WO2023249354A1 (ko) | 디메틸제일아스테럴을 포함하는 근육 감소로 인한 질환 예방 또는 치료용 약학 조성물 | |
WO2022211396A1 (ko) | 배암차즈기 추출물 또는 이의 유래 화합물을 유효성분으로 포함하는 근위축 예방 또는 치료용 약학적 조성물 | |
WO2023277461A1 (ko) | 20(s)-진세노사이드 rg3를 유효성분으로 포함하는 퇴행성 뇌질환 예방 또는 치료용 약학적 조성물 | |
WO2024080435A1 (ko) | 파르네솔을 포함하는 근육 줄기세포 증식 및 분화 촉진용 조성물. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21911553 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023562446 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18258578 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180087261.X Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021911553 Country of ref document: EP Effective date: 20230724 |